Bionano Genomics (NASDAQ: BNGO) saw its stock soar 10.88% in intraday trading on Friday, building on the momentum gained from its impressive third-quarter 2025 financial results released the previous day. The genome analysis company's strong performance and optimistic future outlook have ignited investor enthusiasm, driving the significant stock price increase.

The Q3 results, announced after market close on Thursday, showcased substantial improvements across key metrics. Bionano reported Q3 revenue of $7.4 million, representing a 21% increase from the same period last year and surpassing analyst expectations. The company's gross margin reached an impressive 46%, a remarkable turnaround from the negative 139% reported in Q3 2024. Operating expenses were also reduced by 66% to $11.9 million, demonstrating strong cost management.

Looking ahead, Bionano provided an optimistic outlook for the fourth quarter and full year 2025. The company initiated Q4 2025 revenue guidance in the range of $7.5 to $7.9 million and reiterated its full-year 2025 revenue forecast of $26 to $30 million. Additionally, Bionano now expects to surpass 25 new Optical Genome Mapping (OGM) system installations for the full year 2025, exceeding previous expectations. CEO Erik Holmlin's confident remarks about the company's strategic shift and turn toward sustainable growth have further bolstered investor confidence, contributing to the substantial stock price increase observed on Friday.